Compare TCI & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCI | IMRX |
|---|---|---|
| Founded | 1983 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.7M | 340.7M |
| IPO Year | 1994 | 2021 |
| Metric | TCI | IMRX |
|---|---|---|
| Price | $38.17 | $5.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $17.20 |
| AVG Volume (30 Days) | 3.3K | ★ 724.7K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 135.29 | 37.75 |
| EPS | ★ 1.60 | N/A |
| Revenue | ★ $49,060,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.99 | ★ N/A |
| Revenue Growth | ★ 4.23 | N/A |
| 52 Week Low | $27.06 | $1.10 |
| 52 Week High | $59.65 | $10.08 |
| Indicator | TCI | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.07 | 45.36 |
| Support Level | $33.50 | $4.66 |
| Resistance Level | $42.76 | $5.36 |
| Average True Range (ATR) | 1.22 | 0.41 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 33.38 | 3.09 |
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates in two business segments: the acquisition, development, ownership and management of multifamily properties; and the acquisition, development, ownership and management of commercial properties; which are office properties. The services for its commercial segment include rental of office space and other tenant services, including parking and storage space rental. The services for its multifamily segment include rental of apartments and other tenant services, including parking and storage space rental. the company derives maximum revenue from Multifamily Segment.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.